Exp Clin Endocrinol Diabetes 2010; 118(10): 730-734
DOI: 10.1055/s-0030-1249671
Article

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinases-1 Levels in Severely Obese Patients: What is the Effect of Weight Loss?

D. Papazoglou1 , K. Papatheodorou1 , N. Papanas1 , T. Papadopoulos1 , T. Gioka2 , G. Kabouromiti2 , S. Kotsiou1 , E. Maltezos1
  • 1Medical School of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece
  • 2Laboratory of Biochemistry, University Hospital of Alexandroupolis, Alexandroupolis, Greece
Further Information

Publication History

received 04.01.2010 first decision 09.02.2010

accepted 28.02.2010

Publication Date:
01 April 2010 (online)

Abstract

Introduction: There is increased evidence that circulating levels of matrix metalloproteinases and their tissue inhibitors are altered in obesity and may be implicated in its pathogenesis. This study aimed to compare the serum concentrations of pro-matrix metalloproteinase-1 (pro-MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in severely obese patients with or without metabolic syndrome, and to investigate the potential effect of weight loss on their circulating levels.

Methods: A total of 102 severely obese subjects were included in our study. Of these, 61 had no other features of metabolic syndrome, while the rest were 41 age- and sex-matched subjects with severe obesity and metabolic syndrome according to the NCEP-ATP criteria. Fourty-two age and sex-matched healthy lean individuals were used as controls.

Results: Severely obese subjects had higher circulating levels of TIMP-1 than the lean ones (120.6±50.6 vs. 89.0±35.2 ng/ml) and obese patients with metabolic syndrome had higher TIMP-1 levels than their metabolically healthy counterparts (134.8±38.4 vs. 111.0±55.62 ng/ml). A positive association was also found between TIMP-1 levels and various anthropometric and metabolic parameters in the obese subjects. Moreover, weight loss of more than 5% resulted in a significant reduction of the TIMP-1 levels in obese subjects, irrespective of the presence or not of metabolic syndrome. No significant differences in pro-MMP-1 concentrations were found between the obese (2.8±2.4 ng/ml) and lean individuals (2.8±0.8 ng/ml).

Conclusions: In conclusion, we demonstrated that increased TIMP-1 serum levels are found in severely obese patients and particularly in these with metabolic syndrome, while weight loss of more than 5% resulted in reduction of TIMP-1 levels.

References

Correspondence

Dr. D. Papazoglou

Medical School of Alexandroupolis

Democritus University of Thrace

Patriarhou Grigoriou 97–99

68100 Alexandroupolis

Greece

Phone: +30 2551074725

Fax: +30 2501074723

Email: dapap@otenet.gr